Diabetic Macular Edema

Extended dosing with faricimab offers non-inferior vision gains in DME, wet AMD

Faricimab (Genentech) offered non-inferior vision gains given at intervals of up to 4 months compared to aflibercept given every 2 months in patients with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME), according to a press release. In the four pphase 3 studies (the YOSEMITE and RHINE studies...